Dyne Therapeutics

This July, join the Myotonic Dystrophy Foundation (MDF) for Myotonic Dystrophy in Motion Awareness Month, an initiative to educate and inspire those with myotonic dystrophy (DM) about the power of movement. MDF will host weekly activities, expert webinars and offer opportunities to connect. Learn more and get involved: https://bit.ly/40lcXJZ

On Dyne Science Day, our #Dynamos came together to learn from our scientists about the research, insights and innovation driving our goal to deliver functional improvement for people living with neuromuscular diseases. Thank you to our Scientists for cultivating a spirit of curiosity and fearless innovation.

This #WorldFSHDDay, we’re proud to stand with the FSHD Society and the FSHD community to raise awareness of facioscapulohumeral muscular dystrophy and one of its most visible symptoms: the loss of the ability to smile. Join us in spreading awareness. Snap an orange slice selfie and learn more: https://bit.ly/3xmOSXP

RNA therapeutics are transforming the landscape of drug development. Dyne’s Chief Innovation Officer, Oxana Beskrovnaya, will join leaders across industry and academia at #BIO2025 to discuss what’s driving this momentum. The panel will explore the breakthroughs powering the “RNAissance” and how innovation and investment are accelerating the next wave of RNA-based medicines. Learn more: https://bit.ly/3HL2GQy

We’re excited to join the Duchenne community for the Parent Project Muscular Dystrophy’s 2025 Annual Conference! Register to visit us either virtually or in person at our booth: https://bit.ly/444t0wF

Today we announced that DYNE-101 received Breakthrough Therapy Designation for myotonic dystrophy type 1 from FDA. New long-term data support its promise to deliver meaningful functional improvement as we advance toward potential U.S. Accelerated Approval. Learn more: https://bit.ly/4laT9Rn

Tomorrow, June 17, we will host a webcast to provide an update on DYNE-101 in DM1 Join us at 8:00 a.m. ET: https://bit.ly/3FRUEoA

We were honored to host Dr. Johanna Hamel for a special discussion where she shared compelling insights from her clinical research at the University of Rochester on myotonic dystrophy. Dr. Hamel’s talk explored tracking disease progression, as well as expanding access to studies and registries through remote assessments. Her message was clear: to truly understand rare diseases like DM1 and DM2, we must find ways to make studies accessible for all patients, not just those who can make it to a clinic or research center. Thank you, Dr. Hamel, for the work you do and for reminding us why inclusivity is essential to scientific progress.

We’re looking forward to joining the community at FSHD Connect Europe, an event that brings together individuals living with FSHD, their families, researchers and advocates. It’s an important opportunity to connect, learn and discuss the latest research and advancements aimed at improving the lives of those living with FSHD. Learn more about the event, which is hosted by FSHD Society and FSHD Europe/ FSHD European Trial Network: https://bit.ly/3FGBXEj

Dyne recently joined the Jett Foundation’s National Challenge with a walk in our local park to support the fight against Duchenne muscular dystrophy (DMD). A big thank you to all our #Dynamos who participated to raise awareness and funds for the #DMD community. You can make a difference too. Donate today and help us fuel hope and progress: https://bit.ly/4jwH8oK #NationalChallenge